Skip to main content
Aurinia Pharmaceuticals Inc. logo

Aurinia Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · AUPH ISIN · CA05156V1022 LEI · 5299008YP2BW4570ML28 US Manufacturing
Filings indexed 579 across all filing types
Latest filing 2026-04-03 Regulatory Filings
Country US United States of America
Listing US AUPH

About Aurinia Pharmaceuticals Inc.

https://www.auriniapharma.com

Aurinia Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on developing and delivering therapies for patients with severe autoimmune diseases that have high unmet medical needs. The company's principal product is LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN), a serious complication of systemic lupus erythematosus. Aurinia's research and development efforts are centered on immunomodulating therapies for various autoimmune and kidney-related diseases.

Recent filings

Filing Released Lang Actions
8-K - Aurinia Pharmaceuticals Inc. (0001600620) (Filer)
Regulatory Filings
2026-04-03 English
8-K - Aurinia Pharmaceuticals Inc. (0001600620) (Filer)
Regulatory Filings
2026-03-23 English
4 - AURINIA PHARMACEUTICALS INC. (0001600620) (Filer)
Director's Dealing
2026-03-03 English
4 - AURINIA PHARMACEUTICALS INC. (0001600620) (Filer)
Director's Dealing
2026-03-03 English
4 - AURINIA PHARMACEUTICALS INC. (0001600620) (Filer)
Director's Dealing
2026-03-03 English
4 - AURINIA PHARMACEUTICALS INC. (0001600620) (Filer)
Director's Dealing
2026-03-03 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.